Node-negative patients in the IHC3-Q4 subgroup had a 2-year iDFS rate of 94% and patients in the 10th decile had a 2-year iDFS of 91%, which is comparable to the control arm of the Ki-67-low cohort of the monarchE population (node-positive HRpos/HER2neg early breast cancer with high risk of recurrence).13 This evidence concerns the gene MKI67 and breast carcinoma.